http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015536993-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate | 2013-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2015536993-A |
| titleOfInvention | (1S) -1- [5-({3-[(2-methylpyridin-3-yl) oxy] -5- (pyridin-2-ylsulfanyl) pyridin-2-yl} amino) -1,2, Crystal form of 4-thiadiazol-3-yl] ethane-1,2-diol |
| abstract | The present invention relates to (1S) -1- [5-({3-[(2-methylpyridin-3-yl) oxy] -5- (pyridin-2-ylsulfanyl) pyridin-2-yl} amino)- It relates to crystalline polymorphic forms of 1,2,4-thiadiazol-3-yl] ethane-1,2-diol, pharmaceutical compositions comprising such crystalline polymorphic forms, and processes for preparing them. The invention further relates to a method for the treatment of diabetes-related disorders comprising administering such a solid state form or composition thereof to a subject, and the use of such crystalline polymorphic forms in the manufacture of a medicament. [Selection] Figure 10 |
| priorityDate | 2012-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 892.